Skinvisible (SKVI) Revenue Growth (5y) (2015 - 2026)
Powered by 
Analysis
Skinvisible (SKVI) Revenue Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.02 Bn | 629.26 Bn | 17.26 Bn |
| 2 | AbbVie | 443.38 Bn | 436.81 Bn | 12.70 Bn |
| 3 | Merck | 368.22 Bn | 361.07 Bn | 12.21 Bn |
| 4 | Novartis Ag | 270.16 Bn | 262.47 Bn | 11.24 Bn |
| 5 | Pfizer | 158.63 Bn | 146.93 Bn | 10.94 Bn |
| 6 | Sanofi | 52.92 Bn | 45.54 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.49 Bn | 44.49 Bn | - |
| 8 | Incyte | 25.22 Bn | 20.69 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.17 Bn | 18.51 Bn | 683.80 Mn |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -55.52% |
| Mar 31, 2026 | -16.13% |
| Dec 31, 2025 | -30.75% |
| Sep 30, 2025 | 13.69% |
| Jun 30, 2025 | -46.20% |
| Mar 31, 2025 | -20.81% |
| Dec 31, 2024 | -14.25% |
| Sep 30, 2024 | -15.04% |
| Jun 30, 2024 | -17.03% |
| Mar 31, 2024 | -9.78% |
| Dec 31, 2023 | -17.08% |
| Sep 30, 2023 | -23.17% |
| Jun 30, 2023 | -25.84% |
| Mar 31, 2023 | -20.39% |
| Dec 31, 2022 | -60.40% |
| Sep 30, 2022 | -31.42% |
| Jun 30, 2022 | 37.48% |
| Mar 31, 2022 | 36.82% |
| Dec 31, 2021 | 58.06% |
| Sep 30, 2021 | 45.98% |